Identifying Exifone as a Dual-Target Agent Targeting Both SARS-CoV-2 3CL Protease and the ACE2/S-RBD Interaction Among Clinical Polyphenolic Compounds
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26052243 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Jiani Lu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Longhua Hospital, Shanghai U…. Hauptthemen laut MEDLINE: Angiotensin-Converting Enzyme 2, SARS-CoV-2, Polyphenols, Coronavirus 3C Proteases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, Shanghai Municipal Science and Technology Major Project, SIMM-SHUTCM Traditional Chinese Medicine Innovation Joint Research Pro-gram.
Abstract (Originalsprache)
The ongoing emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has led to resistance against multiple coronavirus disease 2019 (COVID-19) vaccines and therapeutic medications, making the development of effective therapeutics against SARS-CoV-2 a high priority. Studies have shown that bioactive polyphenols, particularly those with triphenol groups, can effectively inhibit the activity of SARS-CoV-2 3-chymotrypsin-like protease (3CLpro). However, the structural instability of polyphenols necessitates further research. To address this, we conducted a literature review to identify triphenol compounds that are either approved or currently undergoing clinical trials, assessing their potential to inhibit SARS-CoV-2 3CLpro. Exifone and benserazide hydrochloride were identified as the inhibitors of SARS-CoV-2 3CLpro among these compounds, using a fluorescence resonance energy transfer (FRET)-based assay. Benserazide hydrochloride was confirmed as a covalent binder to SARS-CoV-2 3CLpro through time-dependent inhibition and kinetic analysis, with its binding mode elucidated by molecular docking. Notably, exifone not only inhibited the protease activity but also blocked the interaction between the host cell receptor angiotensin-converting enzyme 2 (ACE2) and the SARS-CoV-2 spike protein receptor binding domain (S-RBD), as identified by surface plasmon resonance (SPR) and flow cytometry. Additionally, exifone demonstrated antiviral activity against various SARS-CoV-2-S pseudovirus variants. In conclusion, the discovery of exifone and benserazide hydrochloride underscores the potential of polyphenols in developing conserved 3CLpro inhibitors for coronaviruses, offering new strategies for the rapid development of effective drugs against both current and future coronavirus pandemics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
- Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.
- Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Academy of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 201…
- School of Pharmacy, Henan University, Kaifeng 475001, China.
ORCID-Profile: Lili Chen
Förderung
- National Key Research and Development Program of China
- Shanghai Municipal Science and Technology Major Project
- SIMM-SHUTCM Traditional Chinese Medicine Innovation Joint Research Pro-gram
- National Natural Science Foundation of China
- SIMM-SHUTCM Traditional Chinese Medicine Innovation Joint Research Program
Zitieren
APA
Lu, J., Tang, Y., Li, H., Chen, X., Qin, P., Xu, J., Li, W., & Chen, L. (2025). Identifying Exifone as a Dual-Target Agent Targeting Both SARS-CoV-2 3CL Protease and the ACE2/S-RBD Interaction Among Clinical Polyphenolic Compounds. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26052243
Vancouver
Lu J, Tang Y, Li H, Chen X, Qin P, Xu J, et al. Identifying Exifone as a Dual-Target Agent Targeting Both SARS-CoV-2 3CL Protease and the ACE2/S-RBD Interaction Among Clinical Polyphenolic Compounds. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26052243
BibTeX
@article{Lu2025,
author = {Lu, Jiani and Tang, Yan and Li, Hongtao and Chen, Xixiang and Qin, Pengcheng and Xu, Jianrong and Li, Weihua and Chen, Lili},
title = {Identifying Exifone as a Dual-Target Agent Targeting Both SARS-CoV-2 3CL Protease and the ACE2/S-RBD Interaction Among Clinical Polyphenolic Compounds},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26052243}
}
EUVIMED